Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Al-Sharaa denies he called for 80% of Syrians to return from Germany - 2Governments take targeted action as fuel prices hit retail
- 3Artemis II crew take new photo of far side of the moon
- 4How did I get my own unique set of fingerprints?
- 5'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Discovery of massive spider's web in Greece reveals unexpected behavior
- Arctic sea ice hits lowest winter level as unprecedented heat hits smashes records all over Earth
- Transcript: NASA's Jared Isaacman on "Face the Nation with Margaret Brennan," April 5, 2026
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Which Brilliant Home Gadget Can't You Reside Without?
- Scientists are getting our robotic explorers ready to help send humans to Mars
- Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
